Heartland Advisors Inc. decreased its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 4.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,000,000 shares of the medical instruments supplier’s stock after selling 100,000 shares during the quarter. Heartland Advisors Inc. owned 5.74% of Harvard Bioscience worth $7,500,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Dimensional Fund Advisors LP increased its stake in shares of Harvard Bioscience by 1.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,631,348 shares of the medical instruments supplier’s stock valued at $4,242,000 after buying an additional 20,499 shares during the period. Renaissance Technologies LLC increased its stake in shares of Harvard Bioscience by 5.9% in the first quarter. Renaissance Technologies LLC now owns 560,500 shares of the medical instruments supplier’s stock valued at $1,457,000 after buying an additional 31,300 shares during the period. Essex Investment Management Co. LLC increased its stake in shares of Harvard Bioscience by 38.7% in the second quarter. Essex Investment Management Co. LLC now owns 429,460 shares of the medical instruments supplier’s stock valued at $1,095,000 after buying an additional 119,878 shares during the period. Foundry Partners LLC increased its stake in shares of Harvard Bioscience by 2.8% in the second quarter. Foundry Partners LLC now owns 684,775 shares of the medical instruments supplier’s stock valued at $1,746,000 after buying an additional 18,575 shares during the period. Finally, Glacier Peak Capital LLC increased its stake in shares of Harvard Bioscience by 9.8% in the second quarter. Glacier Peak Capital LLC now owns 1,316,993 shares of the medical instruments supplier’s stock valued at $3,358,000 after buying an additional 117,418 shares during the period. 60.87% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Harvard Bioscience, Inc. (HBIO) Shares Sold by Heartland Advisors Inc.” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://theolympiareport.com/2017/10/31/harvard-bioscience-inc-hbio-shares-sold-by-heartland-advisors-inc.html.

Several research analysts have recently issued reports on the company. ValuEngine raised Harvard Bioscience from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. TheStreet raised Harvard Bioscience from a “d+” rating to a “c-” rating in a research note on Monday, July 31st. Finally, Zacks Investment Research raised Harvard Bioscience from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Wednesday, July 12th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $4.75.

Harvard Bioscience, Inc. (NASDAQ HBIO) traded down 0.75% on Tuesday, hitting $3.30. The stock had a trading volume of 5,592 shares. The stock’s market capitalization is $114.96 million. The company has a 50-day moving average price of $3.55 and a 200-day moving average price of $2.87. Harvard Bioscience, Inc. has a 1-year low of $2.25 and a 1-year high of $3.90.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.03 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.03. The company had revenue of $25.05 million for the quarter, compared to analysts’ expectations of $24.60 million. Harvard Bioscience had a positive return on equity of 1.13% and a negative net margin of 3.16%. Equities analysts predict that Harvard Bioscience, Inc. will post $0.13 earnings per share for the current year.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.